<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Haque R</submitter><funding>California Breast Cancer Research Program</funding><pagination>e71642</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12936983</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Although nearly half of women with metastatic breast cancer (mBC) have hypertension, it is unclear whether hypertension management improves survival. We examined the influence of pharmacologic hypertension management on all-cause and breast cancer-specific mortality in patients with mBC.&lt;h4>Methods&lt;/h4>We conducted a longitudinal cohort study of 1332 female patients with de novo mBC diagnosed 2008-2020, followed through 2021. We calculated person-year (PY) rates of all-cause and breast cancer mortality by use of antihypertensives (monotherapy or polytherapy [one vs. multiple drug classes]). Multivariable Cox regression was used to estimate the association between antihypertensives and mortality.&lt;h4>Results&lt;/h4>Overall, 48.4% of patients with mBC had hypertension, which w</pubmed_abstract><journal>Cancer medicine</journal><pubmed_title>Influence of Hypertension Management on Survival in Patients With Metastatic Breast Cancer.</pubmed_title><pmcid>PMC12936983</pmcid><funding_grant_id>B28TR5470</funding_grant_id><pubmed_authors>Barac A</pubmed_authors><pubmed_authors>Hogan TA</pubmed_authors><pubmed_authors>Silverman A</pubmed_authors><pubmed_authors>Chen LH</pubmed_authors><pubmed_authors>Brady-Rogers M</pubmed_authors><pubmed_authors>Gu Z</pubmed_authors><pubmed_authors>Mukherjee A</pubmed_authors><pubmed_authors>Haque R</pubmed_authors><pubmed_authors>Wallner LP</pubmed_authors></additional><is_claimable>false</is_claimable><name>Influence of Hypertension Management on Survival in Patients With Metastatic Breast Cancer.</name><description>&lt;h4>Background&lt;/h4>Although nearly half of women with metastatic breast cancer (mBC) have hypertension, it is unclear whether hypertension management improves survival. We examined the influence of pharmacologic hypertension management on all-cause and breast cancer-specific mortality in patients with mBC.&lt;h4>Methods&lt;/h4>We conducted a longitudinal cohort study of 1332 female patients with de novo mBC diagnosed 2008-2020, followed through 2021. We calculated person-year (PY) rates of all-cause and breast cancer mortality by use of antihypertensives (monotherapy or polytherapy [one vs. multiple drug classes]). Multivariable Cox regression was used to estimate the association between antihypertensives and mortality.&lt;h4>Results&lt;/h4>Overall, 48.4% of patients with mBC had hypertension, which w</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Mar</publication><modification>2026-07-16T21:55:12.622Z</modification><creation>2026-07-12T03:07:28.554Z</creation></dates><accession>S-EPMC12936983</accession><cross_references><pubmed>41744234</pubmed><doi>10.1002/cam4.71642</doi></cross_references></HashMap>